Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Group 1: Premarket Gainers - Abpro Corporation (ABP) is up 80% at $2.74 [3] - Ichor Holdings, Ltd. (ICHR) is up 18% at $40.50 [3] - Microbot Medical Inc. (MBOT) is up 17% at $2.16 [3] - Credo Technology Group Holding Ltd (CRDO) is up 16% at $143.65 [3] - Energy Services of America Corporation (ESOA) is up 15% at $11.00 [3] - Biomerica, Inc. (BMRA) is up 10% at $2.40 [3] - PodcastOne, Inc. (PODC) is up 9% at $3.28 [3] - Clear Channel Outdoor Holdings, Inc. (CCO) is up 7% at $2.36 [3] - OFG Bancorp (OFG) is up 6% at $44.39 [3] - Onity Group Inc. (ONIT) is up 6% at $44.30 [3] Group 2: Premarket Losers - Tectonic Therapeutic, Inc. (TECX) is down 37% at $15.49 [4] - Upwork Inc. (UPWK) is down 24% at $14.18 [4] - Everbright Digital Holding Limited (EDHL) is down 12% at $3.11 [4] - Fly-E Group, Inc. (FLYE) is down 12% at $2.51 [4] - Amentum Holdings, Inc. (AMTM) is down 11% at $32.34 [4] - ZoomInfo Technologies Inc. (GTM) is down 10% at $6.54 [4] - REGENXBIO Inc. (RGNX) is down 9% at $9.31 [4] - Momentus Inc. (MNTS) is down 8% at $5.90 [4] - The Goodyear Tire & Rubber Company (GT) is down 7% at $9.70 [4] - GRI Bio, Inc. (GRI) is down 6% at $2.30 [4]

FDA Approvals & Rejections - Intellia Therapeutics has received FDA approval to resume its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) targeting hereditary transthyretin amyloidosis with polyneuropathy, increasing target enrollment from 50 to 60 patients [2][4] - Outset Medical's next-generation Tablo Hemodialysis System has been granted FDA 510(k) clearance, making it the first dialysis device to meet enhanced cybersecurity standards, with shipping expected to begin in Q2 2026 [6][7] - OKYO Pharma has received positive feedback from the FDA for its Phase 2b/3 trial design for Urcosimod, a candidate for neuropathic corneal pain, with plans to start the trial in the first half of 2026 [8][9] - REGENXBIO has faced clinical holds on its RGX-111 and RGX-121 gene therapy programs due to a case of CNS tumor in a child treated with RGX-111, although no similar findings were reported in other patients [10][11] - Almirall has received NMPA approval for Seysara in China for treating moderate-to-severe acne vulgaris, expanding its dermatology portfolio in the region [12][13] Clinical Trials - Breakthroughs - Aprea Therapeutics reported early clinical activity for APR-1051 in endometrial cancer, achieving a 50% reduction in target lesion size in a patient with PPP2R1A-mutated uterine serous carcinoma [19][21] - Fractyl Health's Revita demonstrated positive results in weight maintenance after GLP-1 drug discontinuation, showing a 4.5% weight regain compared to 7.5% in the sham group [22][24] - Ascletis Pharma announced positive Phase 3 results for Denifanstat in moderate-to-severe acne vulgaris, focusing on long-term safety in a trial with 240 patients [25][26] - GRI Bio reported new gene expression data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis, showing significant improvements in lung injury and fibrosis progression [27][28] - Cardiff Oncology announced encouraging results from its Phase 2 trial of Onvansertib in RAS-mutated metastatic colorectal cancer, with a well-tolerated regimen and plans to advance to a registrational program [31][32] - Genentech's CT-388 Phase 2 trial for obesity showed a significant placebo-adjusted weight loss of 22.5% at 48 weeks, with a high percentage of participants achieving significant weight loss [34][36] - Sarepta Therapeutics reported positive three-year results from its EMBARK study for ELEVIDYS in Duchenne muscular dystrophy, showing significant slowing of disease progression in treated patients [38][41] Deals - YD Bio Limited has signed a letter of intent to acquire Safe Save Medical for approximately $26.87 million, aiming to enhance its capabilities in advanced cellular therapeutics [14][15][17]

Company Overview - OceanFirst Financial Corp. announced plans to acquire Flushing Financial Corporation in an all-stock deal valued at $579 million [1] - Following the announcement, OceanFirst Financial shares fell 7.4% to $18.15 [1] - Flushing Financial Corporation's shares also declined by 9.5% to $15.28 after the merger agreement was revealed [5] Market Movements - Profusa, Inc. shares surged 112% to $0.1445 after restructuring its senior secured convertible note [4] - Antelope Enterprise Holdings Limited rose 99% to $2.25, while Oriental Culture Holding LTD gained 68% to $0.1395 [4] - Ekso Bionics Holdings, Inc. saw a 54.3% increase to $8.43, attributed to positive investor sentiment [4] - Cemtrex, Inc. climbed 52% to $3.2118 as it returned to profitability despite a going-concern warning [4] Strategic Investments - OceanFirst Financial Corp. and Flushing Financial Corporation announced a $225 million strategic investment from Warburg Pincus as part of their merger agreement [5]

Company Performance - Rezolute, Inc. (NASDAQ:RZLT) experienced a dramatic stock price drop to $1.32, reflecting an 87.93% decrease due to a failed Phase 3 study and subsequent investigation by Holzer & Holzer, LLC [1][6] - Oriental Culture Holding Ltd. (NASDAQ:OCG) saw its stock price decline to $1.57, an 81.95% decrease, potentially influenced by its unaudited financial results for the first half of 2025 [2][6] - C3is Inc. (NASDAQ:CISS) reported a stock price drop to $0.34, a 79.82% decrease, amid broader industry challenges and its financial results for the third quarter [3][6] - GRI Bio, Inc. (NASDAQ:GRI) faced a 54.70% decline in stock price to $0.54, linked to its public offering announcement of $8 million [4][6] - Thunder Power Holdings, Inc. (OTCQB:AIEV) saw its stock price decrease to $0.14, a 49.58% drop, as it reported third-quarter results and plans for asset integration and renewable energy expansion [5] Market Trends - The significant price movements across various sectors, including biotechnology, e-commerce, marine shipping, and electric vehicle manufacturing, indicate heightened volatility in the market [5] - Factors contributing to these declines include company-specific news such as earnings reports and strategic decisions, as well as broader market trends and economic indicators [5]

As filed with the Securities and Exchange Commission on December 9, 2025. Registration No. 333-291999 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 82-4369909 (I.R.S. Employer Identification Number) 2223 Avenida de la Playa, #208 La Jolla, CA 92037 (619) 400-117 ...

As filed with the Securities and Exchange Commission on December 9, 2025. Registration No. 333-291999 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 82-4369909 (I.R.S. Employer Identification Number) 2223 Avenida de la Playa, #208 La Jolla, CA 92037 (619) 400-117 ...

As filed with the Securities and Exchange Commission on December 8, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) (State or other jurisdiction of incorporation or organization) 2223 Avenida de la Playa, #208 La Jolla, CA 92037 ...

Shares of Adobe Inc. ADBE rose sharply in pre-market trading after the company posted better-than-expected third-quarter results and raised its fiscal 2025 outlook after Thursday's closing bell.Adobe reported quarterly earnings of $5.31 per share, which beat the analyst estimate of $5.18. Quarterly revenue came in at $5.99 billion, which beat the Street estimate of $5.91 billion, according to data from Benzinga Pro.Adobe shares jumped 4.4% to $365.80 in the pre-market trading session.Here are some other sto ...

Core Insights - GRI Bio, Inc. is advancing a pipeline of Natural Killer T (NKT) cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company will present its research on the inactivation of iNKT cells and its effects on fibroblast activation and fibrosis at the 2025 ATS International Conference [2] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory, fibrotic, and autoimmune diseases [3] - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity, targeting idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [3]

LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of co ...